An interventional study of Saffron extract (Crocus sativus) and Placebo in Dry Eye Syndrome, sponsored by University of Alicante. Withdrawn at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by University of Alicante · Not applicable, Interventional, and Supportive care
Previous research has demonstrated the effectiveness of AFFRONEYE® / CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to compare the results of clinical tests that evaluate signs and symptoms for the diagnosis of dry eye, between two groups (some that take the dietary supplement and others a placebo), in a sample of university workers and students who suffer from dry eye.
Exclusion Criteria:
Daily intake of one tablet for 84 days.
Dietary Supplement: Saffron extract (Crocus sativus)
Daily intake of one tablet for 84 days. This tablet is organoleptically indistinguishable from the experimental tablet.
Dietary Supplement: Placebo
Daily intake of one tablet for 84 days.
Daily intake of one tablet for 84 days.
Changes from baseline dry eye symptoms at 28, 56 and 84 days
Measured with Ocular Surface Disease Index (OSDI, adapted version to spanish). It consists of 12 items that assess symptoms, functional limitations, and environmental factors related to dry eye. The score ranges from 0 to 100 (worst). Each item is evaluated on a 4-point Likert scale (from 0 to 4). The final score is obtained from (the sum of scores for all questions answered x 25) and divide to total number of questions answered (do not included questions answered N/A); dry eye symptoms are considered from ≥ 13 points.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes with respect to baseline NIBUT at 28, 56 and 84 days
Non-Invasive tear BreakUp Time (NIBUT). It is measured with the Keratograph 5M topographer. It is used to assess tear film stability. It is a non-invasive method to observe and detect the tear film break-up time (measured in seconds). In this case, fluorescein staining can be dispensed with, thus eliminating any influence it may have on the tear film and the results. The region and time course of tear film rupture are automatically measured without user intervention. The software analyses the Placido projecting rings on the tear film and automatically detects any distortion or discontinuity in the reflected annular pattern. The results are recorded with respect to time and space, and translated into a colour-coded map. A positive finding has been reported to be a value \<10 s.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes with respect to baseline TMH at 28, 56 and 84 days
Tear Meniscus Height (TMH). It is measured with the Keratograph 5M topographer. It assesses the height of the lacrimal meniscus (measured in millimetres). Firstly, it provides information on the secretory capacity of the main lacrimal gland and secondly, it may indicate a high evaporation rate, which may, for example, be due to an insufficient lipid layer. It is measured with a ruler from the point of the lower lid margin (below the centre of the pupil) to the upper edge of the lacrimal meniscus. A positive finding has been reported to be a value \<0.2 mm.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes with respect to baseline ocular surface stainings at 28, 56 and 84 days
Ocular surface stains are used to assess epithelial damage to the cornea, conjunctiva, and lid margin. To assess corneal epithelial damage, a fluorescein strip is wet with saline, and a drop is instilled inside the lower temporal lid. Optimal viewing is 1-3 minutes after instillation. A positive result is \>5 corneal spots. To assess conjunctival and lid margin damage, a lissamine green strip is wet with saline, and a drop is instilled inside the lower temporal lid. The observation should occur between 1 and 4 min postinstillation. To assess conjunctival damage, a positive score is \> 9 conjunctival spots. To assess lid margin damage, ≥2 mm in length and/or ≥25% sagittal width is a positive score.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes with respect to baseline lipid layer of the tear film at 28, 56 and 84 days
The thickness of the lipid layer is not uniform throughout its structure and is examined by observing an interferential phenomenon with Keratograph 5M topographer. The ideal pattern is yellow to blue color at around 80-100nm. If excessively colored patterns are observed, this refers to a greater lipid film thickness \>100nm. If, on the other hand, the pattern is gray-white, it indicates a thin or absent lipid layer, causing greater evaporation.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes with respect to baseline MGD at 28, 56 and 84 days
Meibomian Gland Dysfunction (MGD). The morphological changes of these glands are evaluated using the Keratograph 5M topographer using integrated infrared diodes that allow illumination of the everted eyelids. The Meibomian glands are located in the tarsal conjunctiva of the upper and lower eyelids and have the function of producing an oily substance (meibum), which forms the lipid layer of the tear film, protecting it against evaporation of its aqueous phase. The number of meibomian glands should be evaluated in the photographs taken; the larger the area without glands, the greater the DGM.
Time frame: 0 (baseline), 28, 56 and 84 days
Changes from baseline osmolarity at 28, 56 and 84 days
Measured with the Tearlab osmometer. A positive result is considered to be ≥308 mOsm/L in either eye or an interocular difference \>8 mOsm/L.
Time frame: 0 (baseline), 28, 56 and 84 days
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alicante